Recent therapeutic drug progress on neuroendocrine prostate cancer
10.3760/cma.j.cn112330-20200511-00373
- VernacularTitle:前列腺神经内分泌癌药物治疗新进展
- Author:
Zheng CHEN
1
;
Liwei WEI
;
Yuzhuo WANG
;
Yumin ZHUO
Author Information
1. 暨南大学附属第一医院泌尿外科，广州 510630
- From:
Chinese Journal of Urology
2020;41(9):709-712
- CountryChina
- Language:Chinese
-
Abstract:
Neuroendocrine prostate cancer(NEPC) is a prostate cancer subtype with a very high degree of malignancy and a special molecular phenotype.NEPC is not sensitive to endocrine therapy, and there are currently no specific drugs, so there is a lack of effective clinical treatment.New advances in NEPC therapeutic include chemical therapy, targeted drug therapy based on molecular phenotype and other non-targeted drug therapy. This article summarizes the current treatment methods, pharmaceutical, and clinical research results for NEPC, aiming to deepen clinicians' more comprehensive understanding of NEPC patients' treatment strategies.
